Company Analysis

Novavax, Inc. (NVAX)

Nasdaq: NVAX · Biological Products, (No Diagnostic Substances) · Gaithersburg, MD · filing with the SEC since 1996
Grade5.5
◀ Past 5.3● Present 5.7▶ Future 5.6
1 est.

Who runs Novavax, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Jacobs John C
President and CEO. First filing Jan 2023, latest Mar 9, 2026, 0 filings in all.
Officers reporting now
6
of 14 people with a filing in the last fifteen months
Directors reporting now
8
25 people on the record since 2006
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Walker Robert EdwardEVP, R&DApr 2026Apr 16, 2026none
Jacobs John CPresident and CEOJan 2023Mar 9, 2026none
Kelly James PatrickEVP, CFO and TreasurerAug 2021Mar 9, 2026none
Casey Mark JEVP, Chief Legal OfficerDec 2023Mar 9, 2026none
O'Hara ElaineEVP, Chief Strategy OfficerMar 2023Mar 9, 2026none
Draghia-Akli RuxandraEVP, Research & DevelopmentNov 2024Mar 9, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Alton Gregg HdirectorNov 2020Jun 23, 2026none
Douglas RicharddirectorAug 2010Jun 23, 2026none
King Rachel K.directorNov 2018Jun 23, 2026none
Mcglynn Margaret GdirectorDec 2020Jun 23, 2026none
Mott David MdirectorJun 2020Jun 23, 2026none
Newton Charles W.directorApr 2025Jun 23, 2026none
Rodgers Richard JdirectorNov 2022Jun 23, 2026none
Shiver John W.directorMar 2025Jun 23, 2026none
Earlier names on the record11, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton NVAX · research, not advice